Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (421-430 of 487) with videos related to

Pageof 49
Sort By:
Future Oncology (London, England)|June 27, 2025
Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensusHampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced CancersLino Möhrmann, Helen J Huang, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Oncology|October 21, 2016
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 FusionVivek Subbiah, Oliver Holmes, Kyle Gowen, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Pageof 49

Showing results (421-430 of 487) with videos related to

Sort By:
Pageof 49
Future Oncology (London, England)|June 27, 2025
Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensusHampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced CancersLino Möhrmann, Helen J Huang, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Oncology|October 21, 2016
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 FusionVivek Subbiah, Oliver Holmes, Kyle Gowen, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Pageof 49